Roche poised to buy MASH drug developer 89bio for $3.5bn
[ad_1] Roche has dipped its toe in the M&A water with an agreement to buy US biotech 89bio and its late-stage candidate for metabolic dysfunction-associated steatohepatitis (MASH). The $14.50-per-share deal equates to a purchase price of $2.4 billion at closing, with Roche dangling another $6 per share in the form of a contingent value right…